{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["43(4)"],"submitter":["Blanchard-Rohner G"],"pubmed_abstract":["Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This "],"journal":["The Pediatric infectious disease journal"],"pagination":["361-364"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10919269"],"repository":["biostudies-literature"],"pubmed_title":["COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children."],"pmcid":["PMC10919269"],"pubmed_authors":["Iglowstein I","Woerner A","Perez MH","Martin AL","Seiler M","Vanoni F","von Kalckreuth C","Pavlovic M","Schwendener Scholl K","Rogdo B","Welzel T","Truck J","Gysi S","Janz I","Wechselberger K","Mettauer N","Severi Conti A","Vaezipour N","Mazzara C","Koehler H","Wachinger T","Swissped RECOVERY Trial Group","Beck I","Agyeman P","Donner B","Duppenthaler A","Rohr M","Amiet V","Wagner N","Zimmermann P","Wutz D","Cudre-Cung HP","Bieri A","Pallivathukal S","Donas A","Meyer A","Trachsel D","Faust SN","Whittaker E","Polito A","Aebi C","Grazioli S","Atkinson A","Riedel T","Kottanattu L","Zutter A","Hofer M","Birkenmaier A","Longchamp D","Hammer J","Lutolf Erni M","Kaiser D","Bielicki JA","Germann S","Kohns M","Zohrer K","Heininger U","Schobi N","Weber K","Bressieux-Degueldre S","Peter Kuen H","Reppucci D","Ferry T","Oppenheim R","Hrup K","Bailey DGN","Lorenz P","Buettcher M","Flade M","Natterer J","Meyer Sauteur P","Bordessoule A","Glockler M","Sanchez C","Blanchard-Rohner G","L'Huillier A","Brotschi B","Schlapbach LJ","Stritt J","Schlaeppi C","Pachlopnik Schmid J","Prader S","Andre MC"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children.","description":"Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-12T10:07:20.159Z","creation":"2025-04-04T12:34:34.494Z"},"accession":"S-EPMC10919269","cross_references":{"pubmed":["38241661"],"doi":["10.1097/INF.0000000000004206"]}}